irinotecan has been researched along with Malignant Mesothelioma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aigner, C; Bankfalvi, A; Hegedüs, B; Hegedüs, L; Mairinger, F; Okumus, Ö; Ploenes, T; Reuter, S; Schuler, M; Theegarten, D; Vega-Rubin-de-Celis, S; Welt, A | 1 |
| Doi, H; Ishigaki, H; Kijima, T; Kitajima, K; Koda, Y; Kuribayashi, K; Minami, T; Nakajima, Y; Nakamura, A; Takahashi, R; Yokoi, T | 1 |
| Andre, T; Aoun, O; Delhorme, JB; Eveno, C; Ferron, G; Gayat, E; Goéré, D; Lo Dico, R; Malgras, B; Marchal, F; Passot, G; Pautrat, K; Pocard, M; Sgarbura, O | 1 |
3 other study(ies) available for irinotecan and Malignant Mesothelioma
| Article | Year |
|---|---|
TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
Topics: Cell Line, Tumor; Humans; Immunoconjugates; Irinotecan; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; RNA | 2023 |
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leukopenia; Male; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Platinum; Progression-Free Survival; Retrospective Studies; Thrombocytopenia | 2021 |
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Doxorubicin; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Mitomycin; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2018 |